Skip to Content

Tag: Sleep Therapy


News

Survey finds improving supply for CPAP devices 

March 18, 2024HME News Staff

NEW YORK – Respondents saw a 6% increase in sleep patient volume, on average, in the last 12 months, according to the HME Sleep and Oxygen Survey for the first quarter of 2024 from Needham and Co.  Respondents expect 6.5% growth in the next 12 months.  “We suspect that the increase is due to improving flow generator supply and HMEs engaging both new and backlogged patients that resulted from the Philips Respironics recall,” the report stated.  Other...

CPAP Device, Needham, Patient volume, Sleep Therapy


Read Full Articlered right arrow icon

OM highlights diabetes, downplays weight loss drugs 

Providers

OM highlights diabetes, downplays weight loss drugs 

November 8, 2023Theresa Flaherty, Managing Editor

RICHMOND, Va. – Owens & Minor officials are excited about the future of the Patient Direct segment after posting double-digit growth for the diabetes and sleep categories in the third quarter.  The segment, which reported revenue of $648 million in the quarter, now makes up about 25% of overall revenue.  “(Diabetes and sleep) continue to be extremely strong for us,” said Edward Pesicka, president and CEO, during a recent earnings call. “And you think about...

Apria, Diabetes, Owens & Minor, Sleep Therapy


Read Full Articlered right arrow icon

Vendors

Nyxoah, ResMed partner in Germany to accelerate sleep therapy 

October 2, 2023HME News Staff

MOUNT SAINT GUIBERT, Belgium – Nyxoah, a med tech company focused on the development and commercialization of innovative solutions to treat obstructive sleep apnea, has announced a partnership with ResMed Germany to increase awareness and therapy penetration in the German market.  The companies will establish a continuum of care that will educate and guide OSA patients in the German market from diagnosis through treatment.  "It is our joint goal to enable more patients to receive...

Germany, Nyxoah, ResMed, Sleep Therapy


Read Full Articlered right arrow icon

Also Noted

Inspire names former Medtronic exec as chief strategy officer 

July 24, 2023HME News Staff

MINNEAPOLIS – Inspire Medical Systems, the maker of an FDA-approved neurostimulation device to treat obstructive sleep apnea, has appointed Carlton Weatherby as chief strategy officer effective July 24. “We are very excited to welcome Carlton to the Inspire team,” said Tim Herbert, president and CEO of Inspire Medical Systems. “Carlton’s vast experience in leadership roles across medtech, as well as his strategic vision, will be very valuable to us as we continue to...

Carlton Weatherby, Inspire Medical Systems, neurostimulation device, Sleep Therapy


Read Full Articlered right arrow icon

Lucile Blaise

Vendors

New sleep leader targets reimbursement, data privacy

October 21, 2022Liz Beaulieu, Editor

  SAN DIEGO – As Lucile Blaise takes on a larger role at ResMed, she is prioritizing, among other things, advocating for new forms of reimbursement for digital health.  Here’s what Blaise, who was promoted from ResMed’s vice president of Sleep & Respiratory Care for Western Europe to president of its global business this summer, had to say about why everyone wins when sleep apnea is diagnosed and treated.  HME News: CEO Mick Farrell often talks about the...

Lucile Blaise, ResMed, Sleep Therapy


Read Full Articlered right arrow icon

Also Noted

SleepRes introduces V̇-Com 

June 6, 2022HME News Staff

NASHVILLE, Tenn. – SleepRes has entered the sleep therapy market with V̇-Com, a device that softens peak inspiratory flow to make CPAP devices more comfortable and increase adherence. “This may be the most important comfort factor in the PAP circuit since we developed BiPAP over 30 years ago,” said Eugene Scarberry, retired senior staff engineer at Philips Respironics for 35 years. “At the end of the day it is all about adherence and the V̇-Com is a whole new approach to...

CPAP Therapy, inspiratory flow, Sleep Therapy, SleepRes


Read Full Articlered right arrow icon

Vendors

ResMed: ‘Our third-quarter results reflect strong performance’

April 28, 2022HME News Staff

SAN DIEGO – ResMed reported revenue increased 12% to $864.5 million in its third quarter fiscal year 2022. The company reported revenue, excluding software-as-a-service, increased 18% in the United States, Canada and Latin America, primarily due to a recall by one of its competitors and a recovery of core sleep patient flow that has been impacted by the COVID-19 pandemic. “Our third-quarter results reflect strong performance across our business, resulting in double-digit top-line...

CPAP Recall, Financial Results, ResMed, Sleep Therapy


Read Full Articlered right arrow icon

Vendors

Philips: Sales were down, orders were up in Q4, 2021

January 24, 2022HME News Staff

AMSTERDAM, the Netherlands – Philips’ comparable sales decreased 32% in the fourth quarter of 2021 for the Connected Care business due, in part, to a double-digit decline in Sleep & Respiratory Care associated with the recall.  For the full year, the Connected Care business recorded a 23% comparable sales decrease.  “Patient well-being is at the heart of everything we do at Philips, and we remain extremely focused on repairing and replacing the devices related to...

Philips earnings, Philips Recall, Respiratory Therapy, Sleep Therapy


Read Full Articlered right arrow icon

Also Noted

AppYea invests in sleep monitor

January 3, 2022HME News Staff

FORT WORTH, Texas – AppYea has acquired SleepX and its flagship product DreamIT, a wearable monitoring solution to treat sleep apnea and snoring. Post-merger, the two companies will focus on the further development and commercialization of SleepX’s solution, including investments in R&D and sales and marketing, as well as an upcoming calibration trial. “I am delighted that we have completed the acquisition of SleepX,” said Boris (Bary) Molchadsky, AppYea’s chairman....

monitoring solution, Sleep Therapy, wearable


Read Full Articlered right arrow icon

Also Noted

Bleep attracts funding 

December 13, 2021HME News Staff

MADISON, Wis. – Bleep has been awarded a $1.7 million SBIR grant from the National Institutes of Health to optimize positive airway pressure mask design for use in the home and acute care/hospital settings. The company will use the grant to optimize its Eclipse PAP, which focuses on having no headgear or straps and addressing leaks, and produce the validation data necessary for successful market commercialization. “Eclipse, our generation two product, will not only continue to address...

Bleep, CPAP Mask, Sleep Therapy


Read Full Articlered right arrow icon